CRYOthermy and Radiofrequency ABLation For AVNRT TrEatment

Princess Margaret Hospital, Hong Kong1 site in 1 country520 target enrollmentMarch 2012

ConditionsSupraventricular Tachycardia Atrioventricular Nodal Reentrant Tachycardia

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Supraventricular Tachycardia
Sponsor: Princess Margaret Hospital, Hong Kong
Enrollment: 520
Locations: 1
Primary Endpoint: treatment success rate, defined as proportion of treated patients with both atrioventricular block-free acute procedural success and mid-term success without recurrence at 6 months
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to compare the safety and effectiveness of cryoablation and radiofrequency ablation in the treatment of the commonest kind of supraventricular tachycardia, namely atrioventricular nodal reentrant tachycardia. The study hypothesis is that cryoablation is non-inferior to radiofrequency.

Registry

clinicaltrials.gov

Start Date

March 2012

End Date

September 2017

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Princess Margaret Hospital, Hong Kong

Responsible Party

Principal Investigator

Ngai Yin Chan

Consultant

Princess Margaret Hospital, Hong Kong

Eligibility Criteria

Inclusion Criteria

•Patients who are referred for catheter ablation of supraventricular tachycardia and diagnosis of AVNRT is made by cardiac electrophysiology study

Exclusion Criteria

•Patients who aged less than 18 or over
•Patients who are pregnant.
•Patients who cannot give informed consent.
•Patients who are judged to have severe mental impairment and cannot report symptoms of palpitation during follow-up.
•Patients who had previous AVNRT ablation before.
•Patients who have comorbid congenital heart disease.

Outcomes

Primary Outcomes

treatment success rate, defined as proportion of treated patients with both atrioventricular block-free acute procedural success and mid-term success without recurrence at 6 months

Time Frame: 6 months after treatment